DGK conference 2022

Crystal structures of the selenoprotein glutathione peroxidase 4 in its apo form and in complex with the covalently bound inhibitor ML162

15 Mar 2022, 15:20

20m

Talk Biologic Structure, Function, Reactivity, and Regulation Biocrystallography: Drug Design

Speaker

Roman Hillig

Description

The selenoprotein GPX4 is a potential cancer drug target. Inhibitors covalently target the active site selenocysteine. Co-crystallization with covalent inhibitors initially failed, most likely due to heterogenous covalent modification. A mass spec-based approach to monitor cysteine modification, together with a surface cysteine mutation, enabled the structure determination of GPX4 with the covalent inhibitor ML162 and opens the path to further inhibitor co-complex structures of this drug target.

Presentation materials

Hillig_DGK_2022.pdf